- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Global Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
832
Companies which are more than 50% undervalued based on analyst price target.
832 companies
Dianthus Therapeutics
Market Cap: US$605.9m
A clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
DNTH
US$18.90
7D
-5.4%
1Y
-31.7%
Iovance Biotherapeutics
Market Cap: US$597.7m
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
IOVA
US$1.71
7D
-45.5%
1Y
-84.0%
Xencor
Market Cap: US$579.3m
A clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.
XNCR
US$8.14
7D
1.9%
1Y
-61.8%
KalVista Pharmaceuticals
Market Cap: US$578.7m
A clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
KALV
US$11.35
7D
-7.3%
1Y
-5.5%
AnaptysBio
Market Cap: US$571.5m
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
ANAB
US$19.45
7D
-1.2%
1Y
-24.0%
Replimune Group
Market Cap: US$570.7m
A clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
REPL
US$7.01
7D
-2.1%
1Y
2.9%
Cogent Biosciences
Market Cap: US$556.0m
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$4.88
7D
3.4%
1Y
-36.8%
Bicycle Therapeutics
Market Cap: US$554.7m
A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
BCYC
US$8.01
7D
3.0%
1Y
-64.2%
Immatics
Market Cap: US$554.3m
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
IMTX
US$4.56
7D
3.9%
1Y
-58.8%
Keros Therapeutics
Market Cap: US$547.1m
A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
KROS
US$13.59
7D
-0.9%
1Y
-75.0%
Medigen Vaccine Biologics
Market Cap: NT$16.5b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$50.30
7D
2.7%
1Y
-4.0%
Valneva
Market Cap: €483.1m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.89
7D
-1.3%
1Y
-28.7%
Sionna Therapeutics
Market Cap: US$529.1m
A clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
SION
US$12.00
7D
-6.8%
1Y
n/a
Maravai LifeSciences Holdings
Market Cap: US$524.6m
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
MRVI
US$1.98
7D
-6.6%
1Y
-82.3%
AIM Vaccine
Market Cap: HK$4.1b
Researches, develops, manufactures, and commercializes of vaccine products for human use in the People’s Republic of China.
6660
HK$3.33
7D
-6.2%
1Y
-60.3%
Clarity Pharmaceuticals
Market Cap: AU$800.2m
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$2.49
7D
3.3%
1Y
-35.2%
Tyra Biosciences
Market Cap: US$514.2m
A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
TYRA
US$9.67
7D
5.9%
1Y
-47.6%
Nxera Pharma
Market Cap: JP¥75.0b
Develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom.
4565
JP¥834.00
7D
-7.4%
1Y
-44.4%
Boryung
Market Cap: ₩714.5b
Engages in the manufacture and sale of pharmaceutical products in South Korea and internationally.
A003850
₩8,510.00
7D
0.8%
1Y
-23.5%
Botanix Pharmaceuticals
Market Cap: AU$781.6m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.40
7D
-11.1%
1Y
56.9%
Kura Oncology
Market Cap: US$502.1m
A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
KURA
US$5.73
7D
1.5%
1Y
-73.8%
Stoke Therapeutics
Market Cap: US$490.8m
An early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
STOK
US$8.99
7D
3.8%
1Y
-36.4%
CStone Pharmaceuticals
Market Cap: HK$3.8b
A biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally.
2616
HK$2.82
7D
6.4%
1Y
156.4%
Taysha Gene Therapies
Market Cap: US$486.0m
A clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
TSHA
US$2.37
7D
24.7%
1Y
-23.8%
Mind Medicine (MindMed)
Market Cap: US$481.3m
A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
MNMD
US$6.54
7D
-0.8%
1Y
-27.9%
Opthea
Market Cap: AU$738.8m
A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.
OPT
AU$0.60
7D
0%
1Y
-10.4%
PYC Therapeutics
Market Cap: AU$734.9m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.26
7D
-3.8%
1Y
20.0%
Relay Therapeutics
Market Cap: US$474.9m
Operates as a clinical-stage precision medicines company.
RLAY
US$2.77
7D
-6.1%
1Y
-59.2%
Orchid Pharma
Market Cap: ₹39.8b
A pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.
ORCHPHARMA
₹785.60
7D
-2.2%
1Y
-28.5%
Altimmune
Market Cap: US$467.2m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$5.70
7D
6.3%
1Y
-35.7%
Upstream Bio
Market Cap: US$460.5m
A clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
UPB
US$8.56
7D
-0.2%
1Y
n/a
Arvinas
Market Cap: US$459.1m
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
ARVN
US$6.07
7D
-9.0%
1Y
-81.2%
Eton Pharmaceuticals
Market Cap: US$457.8m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$17.12
7D
-0.6%
1Y
369.0%
Formycon
Market Cap: €409.6m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
FYB
€23.20
7D
-1.7%
1Y
-46.8%
UroGen Pharma
Market Cap: US$455.1m
Engages in the development and commercialization of solutions for urothelial and specialty cancers.
URGN
US$9.87
7D
-2.5%
1Y
-28.4%
Tilray Brands
Market Cap: US$450.2m
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
TLRY
US$0.44
7D
2.1%
1Y
-78.7%